Five artificial intelligence (AI) algorithms for mammography assessment were better at predicting breast cancer risk over five years than the Breast Cancer Surveillance Consortium (BCSC) risk model, according to new retrospective research involving over 13,000 women.
Can artificial intelligence (AI) provide better assessment of breast cancer risk than an established risk model that incorporates clinical factors, age, family history, breast density and other factors?
In a retrospective assessment of negative two-dimensional digital mammography exams from 13,628 women, five mammography AI algorithms consistently outperformed the Breast Cancer Surveillance Consortium (BCSC) risk model for predicting breast cancer risk over a five-year period.
For the study, recently published in Radiology, researchers compared the BCSC risk model to two academic AI mammography algorithms (Mirai (MIT) and Globally-Aware Multiple Instance Classifier (GMIC, New York University)) and three commercially available AI mammography algorithms including MammoScreen (Therapixel), ProFound AI (iCAD) and Mia (Kheiron Medical Technologies).
For incident cancer detection over a five-year period between 2016 to 2021, the BCSC risk model had a time-dependent area under the receiving operating characteristic curve (AUC) of 61 percent in comparison to AUCs ranging between 63 and 67 percent for the five AI mammography algorithms, according to the researchers.
The researchers also found the five AI mammography algorithms outperformed the BCSC risk model for interval cancer detection at one year. The interval cancer risk detection AUC for the AI algorithms ranged from 67 percent to a high of 71 percent for the MammoScreen and Mia AI models versus 62 percent for the BCSC risk model.
“Mammography AI algorithms provide an approach for improving breast cancer risk prediction beyond clinical variables such as age, family history, or the traditional imaging risk biomarker of breast density. The absolute increase in the AUC for the best mammography AI relative to BCSC was 0.09 for interval cancer risk and 0.06 for overall 5-year risk, a substantial and clinically meaningful improvement,” wrote lead study author Vignesh A. Arasu, M.D., Ph.D., an attending radiologist at the Vallejo Medical Center in Vallejo, Calif., and a research scientist within the Division of Research at Kaiser Permanente Northern California in Oakland, Calif.
(Editor’s note: For related content, see “Study: Emerging AI Platform for DBT Shows 23 Percent Increase in Breast Cancer Detection Rate,” “Digital Mammography Meta-Analysis Suggests AI Performs as Well as Radiologists” and “Study: AI Improves Cancer Detection Rate for Digital Mammography and Digital Breast Tomosynthesis.”)
The researchers also pointed out that all five mammography AI algorithms had consistently higher AUCs than the BCSC model for predicting breast cancer risk for every year of the five-year study period.
“Continued strong predictive performance at 1-5 years is surprising and suggests that AI is not only identifying missed cancers but may identify breast tissue features that help predict future cancer development,” noted Arasu and colleagues. “This is analogous to high breast density independently predicting both tissue masking and future cancer risk.”
In regard to study limitations, the study authors acknowledged numerous AI mammography algorithms beyond the five algorithms assessed in the study and noted the possibility of different results with those mammography AI algorithms. They also conceded a lack of information on missing family history in the retrospective data reviewed for the study.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.